2025 Q4 -tulosraportti
Vain PDF
10 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 046 | - | - | ||
| 2 025 | - | - | ||
| 5 500 | - | - | ||
| 675 | - | - | ||
| 6 900 | - | - |
Ylin
0,316VWAP
Alin
0,298VaihtoMäärä
1,2 3 970 464
VWAP
Ylin
0,316Alin
0,298VaihtoMäärä
1,2 3 970 464
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 30.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sitten · MuokattuJust one more question that I can't find anything about. What happened at the end of October 2025. October 20, 2025 when the price went from 1 down to 0.3? Normally it would be due to poor results for a drug candidate or an emission, but it doesn't seem to have been that... Was it only because the financial report was a little worse than hoped?- ·2 päivää sitten · MuokattuCan anyone tell me why this pill should significantly differentiate itself from those that ARE on the market and ARE already very cheap?
·3 päivää sittenI haven't heard this podcast from Dagens Industri with an interview with Elin Trampe from February 9th this year. Perhaps interesting for new shareholders too. https://podcasts.apple.com/us/podcast/dicot-pharma-elin-trampe/id1818802018?i=1000748895064
·1 päivä sittenHere is a short and concise summary of the main points from the podcast episode “Dicot Pharma – Elin Trampe” (from Noterat/DI-podden): 🎙️ Main points from the podcast 1. The Problem: More than half of all men over 40 experience erectile dysfunction, and current medications have limitations. This forms the basis for the research Dicot Pharma is conducting. 2. Dicot Pharma's focus: The company is developing a new potency drug that is intended to have a longer effect than today's leading preparations on the market, with the goal of taking a position in an industry dominated by international companies. 3. Development status: Uppsala-based Dicot Pharma is in the middle of the process of developing this new drug, and the podcast discusses challenges and opportunities for a small biotech company in this field. 4. Market context: The market is large (hundreds of millions affected globally), and there is significant room for improved treatments with longer duration and potentially fewer side effects than current treatments.
·3 päivää sittenAssume that the result of phase 2b is not entirely satisfactory But! what we already have is a Pill that demonstrably works (hard to beat) Vitamins alone are sold for 6 billion in Sweden on an annual basis So a pill for self-medication just in Scandinavia would probably bring in a good sum If you then add Europe USA and the rest of the world yes then you'll probably have to add a number of 100% So my valuation in this case becomes 1,60 ~ 8,00 kr per share (0,30 ?) It would be interesting if someone else has calculated this I might be completely off Good Luck 🤞·3 päivää sittenThe result of 2a was fine and now with the dose adjustment for 2b, I have absolutely no fear of a bad 2b on that front. Of course, there can always be surprises such as previously unseen side effects. I think that side effects are the only thing that can ruin everything, also the possibility that it is widely consumed as "self-medication".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
10 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sitten · MuokattuJust one more question that I can't find anything about. What happened at the end of October 2025. October 20, 2025 when the price went from 1 down to 0.3? Normally it would be due to poor results for a drug candidate or an emission, but it doesn't seem to have been that... Was it only because the financial report was a little worse than hoped?
- ·2 päivää sitten · MuokattuCan anyone tell me why this pill should significantly differentiate itself from those that ARE on the market and ARE already very cheap?
- ·3 päivää sittenI haven't heard this podcast from Dagens Industri with an interview with Elin Trampe from February 9th this year. Perhaps interesting for new shareholders too. https://podcasts.apple.com/us/podcast/dicot-pharma-elin-trampe/id1818802018?i=1000748895064·1 päivä sittenHere is a short and concise summary of the main points from the podcast episode “Dicot Pharma – Elin Trampe” (from Noterat/DI-podden): 🎙️ Main points from the podcast 1. The Problem: More than half of all men over 40 experience erectile dysfunction, and current medications have limitations. This forms the basis for the research Dicot Pharma is conducting. 2. Dicot Pharma's focus: The company is developing a new potency drug that is intended to have a longer effect than today's leading preparations on the market, with the goal of taking a position in an industry dominated by international companies. 3. Development status: Uppsala-based Dicot Pharma is in the middle of the process of developing this new drug, and the podcast discusses challenges and opportunities for a small biotech company in this field. 4. Market context: The market is large (hundreds of millions affected globally), and there is significant room for improved treatments with longer duration and potentially fewer side effects than current treatments.
- ·3 päivää sittenAssume that the result of phase 2b is not entirely satisfactory But! what we already have is a Pill that demonstrably works (hard to beat) Vitamins alone are sold for 6 billion in Sweden on an annual basis So a pill for self-medication just in Scandinavia would probably bring in a good sum If you then add Europe USA and the rest of the world yes then you'll probably have to add a number of 100% So my valuation in this case becomes 1,60 ~ 8,00 kr per share (0,30 ?) It would be interesting if someone else has calculated this I might be completely off Good Luck 🤞·3 päivää sittenThe result of 2a was fine and now with the dose adjustment for 2b, I have absolutely no fear of a bad 2b on that front. Of course, there can always be surprises such as previously unseen side effects. I think that side effects are the only thing that can ruin everything, also the possibility that it is widely consumed as "self-medication".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 046 | - | - | ||
| 2 025 | - | - | ||
| 5 500 | - | - | ||
| 675 | - | - | ||
| 6 900 | - | - |
Ylin
0,316VWAP
Alin
0,298VaihtoMäärä
1,2 3 970 464
VWAP
Ylin
0,316Alin
0,298VaihtoMäärä
1,2 3 970 464
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 30.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
10 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 30.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sitten · MuokattuJust one more question that I can't find anything about. What happened at the end of October 2025. October 20, 2025 when the price went from 1 down to 0.3? Normally it would be due to poor results for a drug candidate or an emission, but it doesn't seem to have been that... Was it only because the financial report was a little worse than hoped?
- ·2 päivää sitten · MuokattuCan anyone tell me why this pill should significantly differentiate itself from those that ARE on the market and ARE already very cheap?
- ·3 päivää sittenI haven't heard this podcast from Dagens Industri with an interview with Elin Trampe from February 9th this year. Perhaps interesting for new shareholders too. https://podcasts.apple.com/us/podcast/dicot-pharma-elin-trampe/id1818802018?i=1000748895064·1 päivä sittenHere is a short and concise summary of the main points from the podcast episode “Dicot Pharma – Elin Trampe” (from Noterat/DI-podden): 🎙️ Main points from the podcast 1. The Problem: More than half of all men over 40 experience erectile dysfunction, and current medications have limitations. This forms the basis for the research Dicot Pharma is conducting. 2. Dicot Pharma's focus: The company is developing a new potency drug that is intended to have a longer effect than today's leading preparations on the market, with the goal of taking a position in an industry dominated by international companies. 3. Development status: Uppsala-based Dicot Pharma is in the middle of the process of developing this new drug, and the podcast discusses challenges and opportunities for a small biotech company in this field. 4. Market context: The market is large (hundreds of millions affected globally), and there is significant room for improved treatments with longer duration and potentially fewer side effects than current treatments.
- ·3 päivää sittenAssume that the result of phase 2b is not entirely satisfactory But! what we already have is a Pill that demonstrably works (hard to beat) Vitamins alone are sold for 6 billion in Sweden on an annual basis So a pill for self-medication just in Scandinavia would probably bring in a good sum If you then add Europe USA and the rest of the world yes then you'll probably have to add a number of 100% So my valuation in this case becomes 1,60 ~ 8,00 kr per share (0,30 ?) It would be interesting if someone else has calculated this I might be completely off Good Luck 🤞·3 päivää sittenThe result of 2a was fine and now with the dose adjustment for 2b, I have absolutely no fear of a bad 2b on that front. Of course, there can always be surprises such as previously unseen side effects. I think that side effects are the only thing that can ruin everything, also the possibility that it is widely consumed as "self-medication".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 046 | - | - | ||
| 2 025 | - | - | ||
| 5 500 | - | - | ||
| 675 | - | - | ||
| 6 900 | - | - |
Ylin
0,316VWAP
Alin
0,298VaihtoMäärä
1,2 3 970 464
VWAP
Ylin
0,316Alin
0,298VaihtoMäärä
1,2 3 970 464
Välittäjätilasto
Dataa ei löytynyt